Pharma antitrust dispute ‘must be arbitrated’, says US court

A US appeals court has upheld its ruling that an antitrust class action against US pharmaceutical conglomerate Johnson & Johnson over an alleged anticompetitive scheme to protect billion-dollar sales of an autoimmune drug must be arbitrated.


Get unlimited access to all Global Arbitration Review content